Dr. Morgan has a research interest in therapies for prostate cancer across its spectrum from localized to advanced disease. He has specific interests in evidence synthesis and evidence-based practice, large observational studies, and multicentre clinical trials.
Dr. Morgan is a radiation oncologist at The Ottawa Hospital Cancer Centre and an Associate Professor in the Division of Radiation Oncology at the University of Ottawa. He holds a Bachelor of Applied Science in Engineering Physics from the University of British Columbia, a Doctor of Medicine from Queen’s University, and a Master of Science in Clinical Trials from the University of London. Prior to starting his practice in Ottawa in 2010, he completed a fellowship in genitourinary clinical oncology at The Royal Marsden Hospital in London. His practice is focused on genitourinary and breast malignancy.
He is a longstanding member of the Genitourinary Disease Site Group of the Cancer Care Ontario Programme in Evidence-Based Care. Between 2016 and 2020, he served as Co-Chair of the Genitourinary Guideline Advisory Group of the American Society of Clinical Oncology. In 2020, he was appointed to the Guidelines Subcommittee of the American Society for Radiation Oncology.
Dr. Morgan serves on the Genitourinary Cancer Committee of NRG Oncology and the Genitourinary Trial Development Committee of the Canadian Cancer Trials Group. He is a member of the steering committees of four large-scale multicentre phase III trials in localized and advanced prostate cancer.
Roy S, Sun Y,
Morgan SC, Wallis CJD, King K, Zhou YM, D’Souza LA, Azem O, Cueto-Marquez AE, Camden NB, Spratt DE, Kishan AU, Saad F, Malone S. Effect of prior local therapy on response to first line androgen receptor axis targeted therapy in metastatic castrate resistant prostate cancer: A secondary analysis of COU-AA-302 trial.
European Urology 2023; 83(6): 571-579.
https://doi.org/10.1016/j.eururo.2023.02.017
Siva S, Correa R, Ali M, Muacevic A, Ponsky L, Ellis RJ, Lo S, Honishi, Swaminath A, Mclaughlin M,
Morgan SC, Cury F, Amahadevan BT, Kaplan I, Chu W, Hannan R, Staehler M, Warner A, Louie A. Five-year outcomes after stereotactic ablative body radiotherapy (SABR) for primary renal cell carcinoma: An individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney).
Lancet Oncology 2022; 23(12): 1508-1516.
https://doi.org/10.1016/S1470-2045(22)00656-8
Roy S, Sayyid R, Saad F, Sun Y, Lajkosz K, Ong M, Klaassen Z, Malone S, Spratt DE, Wallis CJD,
Morgan SC. Addition of docetaxel to androgen receptor axis-targeted therapy and androgen deprivation therapy in metastatic hormone-sensitive prostate cancer: A network meta-analysis.
European Urology Oncology 2022; 5(5): 494-502.
https://doi.org/10.1016/j.euo.2022.06.003
Morgan SC, Holmes OE, Craig J, Grimes S, Malone S, Long-term outcomes of prostate radiotherapy for newly-diagnosed metastatic prostate cancer.
Prostate Cancer and Prostatic Diseases 2021.
https://doi.org/10.1038/s41391-021-00339-y
Virgo KS, Rumble RB, de Wit R, Mendelson DS. Smith TJ, Taplin M, Wade JL, Bennett CL, Scher HI, Nguyen PL, Gleave M,
Morgan SC, Loblaw DA, Sachdev S, Graham DL, Vapiwala N, Sion AM, Simons VH, Talcott J. Initial management of noncastrate advanced, recurrent or metastatic prostate cancer: ASCO guideline update.
Journal of Clinical Oncology 2021.
https://doi.org/10.1200/JCO.20.03256
Spratt DE, Malone S, Roy S, Grimes S, Eapen L,
Morgan SC, Malone J, Craig J, Dess RT, Jackson W, Kishan AU, Mehra R, Kaffenberger S, Morgan T, Reichert Z, Alumkal J, Michalski JM, Lee WR, Pisansky TM, Feng FY, Shipley WU, Sandler HM, Schipper MJ, Roach M, Sun Y, Lawton CA. Prostate radiotherapy with adjuvant androgen deprivation therapy (ADT) improves metastasis-free survival compared to neoadjuvant ADT: An individual patient meta-analysis.
Journal of Clinical Oncology 2021; 39(2): 136-144.
https://doi.org/10.1200/JCO.20.02438
Morgan SC, Morton GC, Berlin A,
Cheung P, Chung P, Ménard C, Pickles T, Souhami L, Warde PR, Lukka HR. Current
topics in radiotherapy for genitourinary cancers: Consensus statements of the
Genitourinary Radiation Oncologists of Canada.
Canadian Urological
Association Journal 2020; 14(11): E588-E593.
https://doi.org/10.5489/cuaj.6649
Malone S, Roy S, Eapen L, E C, MacRae R, Perry G, Bowen J, Samant R,
Morgan SC, Craig J, Malone K, Grimes S. Sequencing of androgen deprivation therapy with external beam radiotherapy in localized prostate cancer: A phase III randomized controlled trial.
Journal of Clinical Oncology 2020; 38(6): 593-601.
https://doi.org/10.1200/JCO.19.01904
Roy S,
Morgan SC. Who dies from prostate cancer? An analysis of the Surveillance, Epidemiology and End Results database.
Clinical Oncology 2019; 31(9): 630-636.
https://doi.org/10.1016/j.clon.2019.04.012
Morgan SC, Hoffman K, Loblaw DA, Buyyounouski
M, Patton C, Barocas D, Bentzen S, Chang M, Efstathiou J, Greany P,
Halvorsen P, Koontz B, Lawton C, Leyrer CM, Lin D, Ray M, and Sandler H.
Hypofractionated radiation therapy for localized prostate cancer: An ASTRO, ASCO, and AUA evidence-based guideline.
Journal of Clinical Oncology 2018;36:3411-3430.
https://doi.org/10.1200/JCO.18.01097
Alibhai SMH, Zukotynski K, Walker-Dilks C, Emmenegger U, Finelli A,
Morgan SC, Hotte SJ, Winquist E, and the Cancer Care Ontario Genitourinary Cancer Disease Site Group. Bone health and bone targeted therapies for non-metastatic prostate cancer: a systematic review and meta-analysis.
Annals of Internal Medicine 2017;167(5):341-350.
https://doi.org/10.7326/M16-2577
Chen R, Rumble RB, Loblaw DA, Finelli A, Ehdaie B,
Cooperberg M,
Morgan SC, Tyldesley S,
Haluschak JJ, Tan W, Justman S, Jain S. Active Surveillance for the management
of localized prostate cancer (Cancer Care Ontario Guideline): American Society
of Clinical Oncology clinical practice guideline endorsement.
Journal of Clinical Oncology 2016;34(18):2182-2190.
https://doi.org/10.1200/JCO.2015.65.7759
Morgan SC, Parker
CC. Local treatment of metastatic cancer—killing the seed or disturbing
the soil?
Nature Reviews Clinical
Oncology 2011;8(8):504-506.
Morgan
SC, Waldron TS, Eapen L, Mayhew LA, Winquist E, Lukka
H, and Members of the Cancer Care Ontario Genitourinary Cancer Disease Site
Group. Adjuvant radiotherapy following
radical prostatectomy for pathologic T3 or margin-positive prostate cancer: a
systematic review and meta-analysis.
Radiotherapy and Oncology 2008;88(1):1-9.
